Skip to main content

Table 6 Kaplan-Meier analysis for DFS between the different treatment regimens

From: The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients

  Mean DFS 95% CI Median 95% CI p value
Endoxan-Dexa 4.444 0.6, 8.3 3 0.0, 11.8 < 0.001*
VCD 29.511 16.4, 42.6 14 6.8, 21.2
VRD 25.613 16.1, 35.2 24 17.5, 30.5
VTD 44.063 24, 64.1 - -
  1. *Significant at p ≤ 0.05
  2. VCD Velcade® (bortezomib)-cyclophosphamide-dexamethasone, VRD Velcade® (bortezomib)-Revlimid® (lenalidomide)-dexamethasone, VTD Velcade® (bortezomib)-thalidomide-dexamethasone, Endoxan-Dexa endoxan-dexamethasone